Proprotein convertase subtilisin kexin 9 inhibitors: Current status and future directions
Journal of Clinical and Preventive Cardiology, 2017 The discovery of proprotein convertase subtilisin kexin 9 (PCSK9) has considerably changed the therapeutic options in the field of lipid management. PCSK9 reduces low-density lipoprotein receptor (LDLR) recycling, leading to a decrease of LDL cholesterol
JPS Sawhney, Saurabh Bagga
doaj +1 more source
The associations between proprotein convertase subtilisin/kexin type 9 E670G polymorphism and the risk of coronary artery disease and serum lipid levels: a meta-analysis [PDF]
, 2015 BACKGROUND: Studies had investigated the associations between proprotein convertase subtilisin/kexin type 9 (PCSK9) E670G polymorphism and coronary artery disease (CAD) and lipid levels, but the results were controversial.
Bifeng Zhang +6 more
core +2 more sources
Perkembangan Implikasi Biologi dan Klinis Proprotein Convertase Subtilisin-Kexin 9
Majalah Kardiologi Indonesia, 2017 Pada tahun 2003 Proprotein Convertase Subtilisin-Kexin 9 (PCSK9) berhasil diidentifikasi.1 PCSK9 berfungsi meningkatkan kadar LDL Cholesterol (LDL-C) melalui degradasi LDL Receptor (LDLR).2 Penemuan PCSK9 telah merevolusi serta merupakan perkembangan ...
doaj +1 more source
Sex difference in circulating PCSK9 and its clinical implications
Frontiers in Pharmacology, 2022 Proprotein convertase subtilisin kexin type 9 (PCSK9) is a proprotein convertase that increases plasma low-density lipoprotein cholesterol (LDL-C) levels by triggering the degradation of LDL receptors (LDLRs).
Fang Jia +4 more
doaj +1 more source
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. [PDF]
, 2017 BACKGROUND: Despite the availability of effective drug therapies that reduce low-density lipoprotein (LDL)-cholesterol (LDL-C), cardiovascular disease (CVD) remains an important cause of mortality and morbidity.
Casas, Juan P +5 more
core +2 more sources
Proprotein convertase subtilisin/kexin type 9 in kidney disease
Nephrology Dialysis Transplantation, 2019 Abstract Chronic kidney disease (CKD) is associated with a substantially increased risk for the development of atherosclerotic cardiovascular (CV) disease. Accordingly, CV mortality is increased even in the earliest stages of CKD. In the general population and in CKD patients, high plasma levels of low-density lipoprotein cholesterol ...
David, Schmit +2 more
openaire +2 more sources
Acute Tubular Injury in a Patient on a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
JACC: Case Reports, 2020 A 72-year-old man with coronary artery disease, statin intolerance, and chronic kidney disease stage IIIa was initiated on alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, and developed acute kidney injury.
June K. Pickett, MD +6 more
doaj +1 more source
Frontiers in Medicine, 2022 BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that is a mediator of the immune response to sepsis. PCSK9 is also highly expressed in pneumocytes and pulmonary endothelial cells.
Thomas S. Metkus +5 more
doaj +1 more source
Molecular Implications of natriuretic peptides in the protection from hypertension and target organ damage development [PDF]
, 2019 The pathogenesis of hypertension, as a multifactorial trait, is complex. High blood pressure levels, in turn, concur with the development of cardiovascular damage.
Forte, Maurizio +3 more
core +1 more source
Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors [PDF]
The Journal of the American Board of Family Medicine, 2018 Coronary artery disease is the leading cause of death in United States. Hyperlipidemia is an independent and potentially reversible risk factor for coronary artery disease. The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, collectively known as statins, have been the mainstay of pharmacologic therapy.
Muhammed, Shahreyar +5 more
openaire +2 more sources